

# Amarnath Challapalli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4159677/publications.pdf>

Version: 2024-02-01

55  
papers

853  
citations

567281

15  
h-index

477307

29  
g-index

55  
all docs

55  
docs citations

55  
times ranked

1548  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular mechanisms of hypoxia in cancer. <i>Clinical and Translational Imaging</i> , 2017, 5, 225-253.	2.1	119
2	Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression. <i>Clinical Cancer Research</i> , 2011, 17, 7673-7683.	7.0	107
3	<sup>18</sup> F-ICMT-11, a Caspase-3 Specific PET Tracer for Apoptosis: Biodistribution and Radiation Dosimetry. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1551-1556.	5.0	83
4	[18F]-3-Deoxy-3-Fluorothymidine Positron Emission Tomography and Breast Cancer Response to Docetaxel. <i>Clinical Cancer Research</i> , 2011, 17, 7664-7672.	7.0	81
5	Imaging apoptosis with positron emission tomography: Bench to bedside development of the caspase-3/7 specific radiotracer [18F]ICMT-11. <i>European Journal of Cancer</i> , 2012, 48, 432-440.	2.8	56
6	Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response Monitoring. <i>Frontiers in Oncology</i> , 2016, 6, 44.	2.8	49
7	Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 78-86.	0.8	46
8	Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma. <i>Future Oncology</i> , 2021, 17, 611-627.	2.4	34
9	Biological basis of [11C]choline-positron emission tomography in patients with breast cancer. <i>Nuclear Medicine Communications</i> , 2011, 32, 997-1004.	1.1	27
10	Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer. <i>Nuclear Medicine Communications</i> , 2014, 35, 20-29.	1.1	25
11	Biodistribution and Radiation Dosimetry of Deuterium-Substituted <sup>18</sup> F-Fluoromethyl-[1, 2- <sup>2</sup> H <sub>4</sub> ]Choline in Healthy Volunteers. <i>Journal of Nuclear Medicine</i> , 2014, 55, 256-263.	5.0	25
12	3-Deoxy-3-18F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 831-840.	6.4	24
13	Imaging of cellular proliferation in liver metastasis by [18F]fluorothymidine positron emission tomography: effect of therapy. <i>Physics in Medicine and Biology</i> , 2012, 57, 3419-3433.	3.0	17
14	Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and [18F] 3-deoxy-3-fluorothymidine PET: a pilot study. <i>Biomarkers in Medicine</i> , 2012, 6, 231-233.	1.4	17
15	Exploiting altered patterns of choline kinase-alpha expression on human prostate tissue to prognosticate prostate cancer. <i>Journal of Clinical Pathology</i> , 2015, 68, 703-709.	2.0	17
16	Implementation of a Daily Transperineal Ultrasound System as Image-guided Radiotherapy for Prostate Cancer. <i>Clinical Oncology</i> , 2017, 29, e49.	1.4	13
17	Thyroid Lymphoma Incidentally Detected by 18F-Fluorocholine (FCH) PET/CT. <i>Clinical Nuclear Medicine</i> , 2013, 38, 755-757.	1.3	12
18	[18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1239-1251.	6.4	12

#	ARTICLE	IF	CITATIONS
19	Spine and Non-spine Bone Metastases – Current Controversies and Future Direction. Clinical Oncology, 2020, 32, 728-744.	1.4	10
20	Cervical paraganglioma – A case report and review of all cases reported to the Manchester Children's Tumour Registry 1954 – 2004. Pediatric Blood and Cancer, 2007, 48, 112-116.	1.5	9
21	A phase II trial of cabazitaxel as second line chemotherapy in relapsed locally advanced and/or metastatic carcinoma of the penis. Journal of International Medical Research, 2019, 47, 4664-4672.	1.0	9
22	Spatial heterogeneity of radiolabeled choline positron emission tomography in tumors of patients with non-small cell lung cancer: first-in-patient evaluation of [ <sup>18</sup> F]fluoromethyl-(1,2- <sup>2</sup> H <sub>4</sub> )-choline. Theranostics, 2020, 10, 8677-8690.	10.0	9
23	Evaluating the prevalence and predictive factors of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy: Results from a single institution experience. Clinical and Translational Radiation Oncology, 2018, 10, 29-35.	1.7	7
24	Radiotherapy and Systemic Treatment for Non-melanoma Skin Cancer in the COVID-19 Pandemic. Clinical Oncology, 2020, 32, 417-419.	1.4	6
25	Development and validation of contouring guidelines for post-cystectomy adjuvant radiation of bladder cancer.. Journal of Clinical Oncology, 2016, 34, 409-409.	1.6	6
26	Cemiplimab in advanced cutaneous squamous cell carcinoma: the UK experience from the Named Patient Scheme. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	5
27	A randomized controlled trial to determine the effect of triptorelin on reduction of prostate volume preradiotherapy compared with standard therapy (goserelin).. Journal of Clinical Oncology, 2016, 34, 30-30.	1.6	4
28	A phase II trial of cemiplimab alone or in combination with standard of care chemotherapy in locally advanced or metastatic penile carcinoma (EPIC Trial).. Journal of Clinical Oncology, 2022, 40, TPS5094-TPS5094.	1.6	4
29	Health-related quality of life in men with metastatic castration-resistant prostate cancer. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 941-949.	1.4	3
30	A Single-arm Phase II Trial of Neoadjuvant Cabazitaxel and Cisplatin Chemotherapy for Muscle-Invasive Transitional Cell Carcinoma of the Urinary Bladder. Clinical Genitourinary Cancer, 2021, 19, 325-332.	1.9	3
31	The Bristol Uro-oncology Complex Case Meeting: A New Model for Patient-centred Care. Clinical Oncology, 2015, 27, e8.	1.4	2
32	Evaluation of 18F-fluorothymidine positron emission tomography ([ <sup>18</sup> F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer. EJNMMI Research, 2016, 6, 81.	2.5	2
33	Upfront docetaxel with androgen deprivation therapy in the elderly patient with metastatic hormone-naïve prostate cancer: Single institution experience.. Journal of Clinical Oncology, 2018, 36, 328-328.	1.6	2
34	Implementing Image-guided Prostate Radiotherapy: Use of the ACCULOC® System to Optimise the Planning Target Volume Margins and to Assess the Potential Clinical Benefit. Clinical Oncology, 2012, 24, 590-591.	1.4	1
35	Development and Validation of Contouring Guidelines for Postcystectomy Adjuvant Radiation of Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, S24-S25.	0.8	1
36	Early Outcomes of 19 Gy Single Fraction High Dose Rate Brachytherapy as Monotherapy for Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, e99-e100.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Rectal spacers in patients with prostate cancer undergoing radiotherapy: A survey of UK urooncologists. International Journal of Clinical Practice, 2021, 75, e14338.	1.7	1
38	Quality of life evaluation of the effect of decapeptyl compared with zoladex preradiotherapy: Final results of randomised controlled trial.. Journal of Clinical Oncology, 2017, 35, 62-62.	1.6	1
39	High dose rate brachytherapy as monotherapy for localized prostate cancer: Our initial experience.. Journal of Clinical Oncology, 2016, 34, e626-e626.	1.6	1
40	[ <sup>18</sup> F] Fluciclatide PET as a biomarker of clinical response to combination therapy of pazopanib and paclitaxel in patients with platinum-resistant or platinum-refractory advanced ovarian cancer: Results of a phase Ib study.. Journal of Clinical Oncology, 2019, 37, 3070-3070.	1.6	1
41	New radiotracers in gynecological cancer: beyond <sup>18</sup> F-FDG. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2016, 60, 139-53.	0.7	1
42	Image Guided HDR Brachytherapy Boost for Locally Advanced Prostate Cancer using Oncentra Prostate HDR Planning System. Clinical Oncology, 2011, 23, S14.	1.4	0
43	Comparing respiratory and patient movement during dynamic PET. , 2012, , .		0
44	Establishing the Use of [ <sup>11</sup> C]Choline PET-CT as an Image-based Biomarker in Prostate Cancer: Evaluation of [ <sup>11</sup> C]Choline Parameters Following Neoadjuvant Androgen Deprivation and Radical Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2012, 84, S184.	0.8	0
45	Efficacy and Toxicity of Hypofractionated Palliative Radiation Therapy for Muscle Invasive Bladder Cancer in the Elderly: A Single Institution Experience. International Journal of Radiation Oncology Biology Physics, 2018, 102, e89-e90.	0.8	0
46	Stage 1 Testicular Seminomas Treated with Single Cycle Carboplatin: Outcomes and Management of Relapse: A Single-Centre Experience. International Journal of Radiation Oncology Biology Physics, 2018, 102, e153.	0.8	0
47	Management and outcomes of stage 2a testicular seminoma: a single-centre experience. Clinical Oncology, 2018, 30, e3.	1.4	0
48	The prevalence of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy: Results from a single-institution experience.. Journal of Clinical Oncology, 2014, 32, 283-283.	1.6	0
49	Radium-223 in metastatic castration resistant prostate cancer: Progression free survival and pain scores—Real-world single-institution experience.. Journal of Clinical Oncology, 2016, 34, 250-250.	1.6	0
50	Second line axitinib in metastatic renal cell carcinoma: Evaluation of prognostic factors influencing outcome.. Journal of Clinical Oncology, 2017, 35, 495-495.	1.6	0
51	Radium-223 in metastatic castration-resistant prostate cancer: Effect of performance score and albumin levels.. Journal of Clinical Oncology, 2017, 35, e594-e594.	1.6	0
52	The Bristol Bladder trial: A single-arm phase II trial of cisplatin and cabazitaxel for muscle invasive transitional cell carcinoma of the urinary bladder prior to radical cystectomy.. Journal of Clinical Oncology, 2018, 36, 468-468.	1.6	0
53	Predictors of improved biochemical progression free survival for salvage prostate bed radiotherapy after radical prostatectomy.. Journal of Clinical Oncology, 2018, 36, 38-38.	1.6	0
54	Muscle-invasive bladder cancer: palliative radiotherapy outcomes. Clinical Medicine, 2019, 19, s61-s61.	1.9	0

#	ARTICLE	IF	CITATIONS
55	Pathological response rates and quality of life outcomes of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle-invasive transitional cell carcinoma of the urinary bladder.. Journal of Clinical Oncology, 2020, 38, 5030-5030.	1.6	0